John Sourbeer
Stock Analyst at UBS
(0.48)
# 3,867
Out of 4,784 analysts
36
Total ratings
27.78%
Success rate
-28.44%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYRX Cryoport | Upgrades: Buy | $10 | $6.09 | +64.20% | 5 | Mar 24, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $20.29 | +15.82% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $34.89 | +28.98% | 3 | Feb 13, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $50 → $48 | $39.85 | +20.45% | 4 | Feb 7, 2025 | |
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $222.20 | +75.52% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.14 | +75.44% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $80.00 | +81.25% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $312.36 | +53.67% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $1.43 | +424.48% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $42.08 | +142.40% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $9.16 | +445.85% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $179.07 | +50.78% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $130.82 | -2.16% | 2 | Jul 27, 2022 |
Cryoport
Mar 24, 2025
Upgrades: Buy
Price Target: $10
Current: $6.09
Upside: +64.20%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $20.29
Upside: +15.82%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $34.89
Upside: +28.98%
Qiagen
Feb 7, 2025
Maintains: Neutral
Price Target: $50 → $48
Current: $39.85
Upside: +20.45%
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $222.20
Upside: +75.52%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.14
Upside: +75.44%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $80.00
Upside: +81.25%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $312.36
Upside: +53.67%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $1.43
Upside: +424.48%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $42.08
Upside: +142.40%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $9.16
Upside: +445.85%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $179.07
Upside: +50.78%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $130.82
Upside: -2.16%